Deal Snapshot
ARREVUS CLOSES ACQUISITION OF FUSIDIC ACID FROM MELINTA THERAPEUTICS
Friday 08 February 2019

US-based biotechnology company Arrevus Inc. has completed the acquisition of fusidic acid from Melinta Therapeutics, the company said.
Arrevus said it is now better positioned to advance its pipeline into clinical use for patients with serious bacterial infections where there is substantial unmet need. Melinta Therapeutics is a commercial-stage company dedicated to developing and commercializing novel antibiotics to treat serious bacterial infections and currently has four FDA-approved antibiotics.


TKUqg0 http://www.FyLitCl7Pf7kjQdDUOLQOuaxTXbj5iNG.com
Details
Date Published: 08/02/2019
Target: fusidic acid
Country: USA
Sector: Biotechnology
Type: Corporate acquisition
Financing:
Status: Closed
Vendor: Melinta Therapeutics
Buyer: Arrevus Inc
Comment:
Fusidic acid received Orphan Drug Designation from the FDA for the treatment of prosthetic joint infection and also received Qualified Infectious Disease Product Designation under the Generating Antibiotic Incentives Now Act.

Options